The 5-Hydroxytryptamine Receptor 1 pipeline drugs market research report outlays comprehensive information on the 5-Hydroxytryptamine Receptor 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the 5-Hydroxytryptamine Receptor 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Gastrointestinal, Immunology, and Undisclosed which include the indications Schizophrenia, Depression, Irritable Bowel Syndrome, Constipation, Autoimmune Disorders, Inflammation, and Unspecified. It also reviews key players involved in 5-Hydroxytryptamine Receptor 1 targeted therapeutics development with respective active and dormant or discontinued products.
The 5-Hydroxytryptamine Receptor 1 pipeline targets constitutes close to 131 molecules. Out of which, approximately 122 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 5, 2, 11, 21, 19, 7, 42, and 13 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical, and Discovery comprises 1, 4, 3, and 1 molecule.
5-Hydroxytryptamine Receptor 1 overview
The 5-hydroxytryptamine receptor 1A (HTR1A), also known as the serotonin 1A receptor, is a protein that in humans is encoded by the HTR1A gene. 5-HT1A is a G protein-coupled receptor (GPCR) that binds serotonin, also known as 5-HT, a neurotransmitter. It is most abundant in the raphe nuclei of the brainstem and the hippocampus, but is also found in other parts of the brain, as well as in the spleen and neonatal kidney.
For a complete picture of 5-Hydroxytryptamine Receptor 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
